Abstract

Patients with elderly-onset IBD are more likely to have marked comorbidities and polypharmacy than those diagnosed at a younger age, which might affect therapeutic decision-making. Increased knowledge of this higher-risk group might guide patient management. Data from a large population-based study evaluating the clinical presentation and course of elderly-onset IBD are discussed.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call